1. ALLA AKTIER
  2. NYHETER
  3. PROSTALUND

ProstaLund

Nyheter ProstaLund Nyheter alla bolag

New agreement - MR Prof. Dr Karl Diehl starts up with CoreTherm® treatments in Austria

ProstaLund has signed an agreement on CoreTherm® with MR Prof. Dr Karl Diehl. The agreement means that MR Prof. Dr Karl Diehl has purchased a CoreTherm® machine and that ProstaLund will educate, sell instruments for CoreTherm® treatments and service the machine. The first CoreTherm® treatments are planned to be performed during the third quarter.

‘It is great news that we are now taking the step into Europe in line with the company's presented strategy, and that we get the opportunity to show and train future new customers in a central location in Europe’ says Anders Kristensson, CEO ProstaLund AB.

For further information, please contact:

Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com

About ProstaLund

ProstaLund AB (publ) is a Swedish medtech company with a headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement. The company has patented the CoreTherm® Concept treatment method, a customised thermal treatment for BPE (Benign Prostatic Enlargement). ProstaLund is listed on Nasdaq First North Growth Market and has approximately 4,000 shareholders. See also - www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments

New agreement - MR Prof. Dr Karl Diehl starts up with CoreTherm® treatments in Austria

Datum 2024-05-31, kl 10:40
Källa MFN
Bifogade filer
New agreement - MR Prof. Dr Karl Diehl starts up with CoreTherm® treatments in Austria
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet